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Available online 26 July 2014Introduction: Focal therapymay reduce the toxicity of current radical treatmentswhilemaintaining
the oncological benefit. Irreversible electroporation (IRE) has been proposed to be tissue selective
and so might have favourable characteristics compared to the currently used prostate ablative
technologies. The aim of this trial is to determine the adverse events, genito-urinary side effects and
early histological outcomes of focal IRE in men with localised prostate cancer.
Methods: This is a single centre prospective development (stage 2a) study following the IDEAL
recommendations for evaluating new surgical procedures. Twenty men who have MRI-visible
disease localised in the anterior part of the prostate will be recruited. The sample size permits a
precision estimate around key functional outcomes. Inclusion criteria include PSA ≤ 15 ng/ml,
Gleason score ≤ 4 + 3, stage T2N0M0 and absence of clinically significant disease outside the
treatment area. Treatment delivery will be changed in an adaptive iterative manner so as to allow
optimisation of the IRE protocol. After focal IRE, men will be followed during 12 months using
validated patient reported outcome measures (IPSS, IIEF-15, UCLA-EPIC, EQ-5D, FACT-P, MAX-PC).
Early disease control will be evaluated by mpMRI and targeted transperineal biopsy of the treated
area at 6 months.
Discussion: The NEAT trial will assess the early functional and disease control outcome of focal IRE
using an adaptive design. Our protocol can provide guidance for designing an adaptive trial to
assess new surgical technologies in the challenging landscape of health technology assessment in
prostate cancer treatment.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).Keywords:
Focal therapy
Health technology assessment
Irreversible electroporation
Prostate cancerInterventional Science,
447 9194; fax: +44 20
alerio).
nc. This is an open access artic1. Introduction
Recent evidence from large randomised controlled trials
(RCTs) in prostate cancer has challenged the current diagnostic
and treatment pathway of the disease [1,2]. This is due to an
unfavourable benefit/risk ratio. This is because of two reasons.
First, many men are diagnosed with indolent prostate cancerle under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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[3,4]. Second, when treatment is given, it is applied in a radical
whole-gland manner (using surgery or radiotherapy) which
causes collateral tissue damage and side effects. In summary,
erectile dysfunction, urinary incontinence and bowel toxicity
occur in about 40–95%, 10–20% and 5–35% of men undergoing
radical therapy, respectively [5].
As a result, one strategy that has been proposed to mitigate
the harms of the current pathway is focal therapy. This involves
targeting therapy to the area of the prostate harbouring
clinically significant disease (cancer that is not indolent and
requires treatment), while sparing the rest of the gland. Indeed,
by preserving prostatic tissue and the important structures
surrounding the prostate — such as external urinary sphincter,
neurovascular bundles, bladder neck, and rectum— the toxicity
profile decreases significantly. A recent systematic review has
shown that various sources of energy have been used for focal
therapy [6]. Overall, erectile dysfunction, urinary incontinence
and bowel toxicity were lower and ranged from 0 to 46%, 0 to
5% and 0 to 33%, respectively [6]. Cancer-control outcomes
demonstrated residual cancer in 4–50% of men having a biopsy
after treatment, although only 0–17% of residual disease was
deemed clinically significant [6].
Currently, most of the energy sources used in a focal manner
utilise a thermal effect to destroy prostatic tissue: cryotherapy
uses temperatures below −40 °C and high-intensity focused
ultrasound therapy (HIFU) use temperatures above+60 °C [6,7].
Thermal tissue destructionmay have some drawbacks. First, it is
non-selective towards the different structures (nerves, stroma,
vasculature, glands) of the prostate and collateral damage could
still occur. Second, especially with high temperatures, the
heat-sink effect of intra- and extra-prostatic vessels (which
can dissipate the energy) can lead to under-treatment. Third,
the precision required to treat an area of prostate to within
millimetre accuracy may be lacking. New technologies in the
field might combine better cancer control outcomes with
enhanced tissue preservation.
Irreversible electroporation (IRE) is a promising new
technology. By using low voltage direct electric current, IRE
permanently damages the cell membrane, and leads to cell
death with no thermal effect [8]. IRE has been used for the
treatment of localised and metastatic tumours in other solid
organmalignancies such as kidney, liver, pancreas and lung [9].
It has some potential advantages that might lend itself to
focal therapy in prostate cancer. First, the tissue outside the
electrical field is theoretically not compromised since there
is no effect in those areas [8]. Second, the treatment has
shown tissue-selectivity in pre-clinical studies, so that collag-
enous structures — such as vessels, nerves and the urethra —
seem not to be affected [8,10,11].
As a result, we hypothesised that IRE would lead to low rate
of side-effects when applied in a focal manner to men with
clinically significant localised prostate cancer. To date, IRE has
been used only in one proof of concept study with no intention
to treat [12]. As a consequence,we followed the IDEAL guidelines
for evaluating surgical innovation which recommends stages of
evaluation and is mirrored upon the UK Medical Research
Council's (MRC) Guidelines of evaluation complex interventions
[13,14].
The optimal trial design for ablative therapies has been
debated and discussed in detail by numerous consensus groupsof clinicians and methodologists [15–17]. The FDA in the US
has also recently held a panel discussion in 2013 to look into
this area [18]. The key problem has been in deciding on a
trial design that shows benefit to patients. While side-effects
could be measured in the short-term, disease control in a
cancer which has a long natural history, is difficult to
determine objectively. Our NEAT protocol, we believe, pro-
vides an exemplar of an adaptive design that would potentially
answer the question about whether there is benefit in terms of
reduced side-effects as well as provide robust data on the
disease control outcomes in the short andmedium term so that
novel therapies can be approved in a timely manner to benefit
men with prostate cancer.2. NEAT protocol
2.1. Study management
NEAT is an investigator led single arm interventional
adaptive trial compliant to the MRC guidelines for evalu-
ating complex procedures, and to stage 2a (prospective
development study) according to the IDEAL guidelines.
Investigators from University College London (UCL) de-
signed the protocol, considering feedback from the Na-
tional Cancer Research Institute (UK) Prostate Clinical
Studies Group as well as from patient representatives. The
study is sponsored by UCL, and will be run at the University
College London Hospital. The Joint Research Office of the local
Research & Development unit is responsible for monitoring
patients' safety and adherence to good clinical practice. The
trial steering committee (TSC) is composed of an indepen-
dent chair, the co-principal investigators, the study coor-
dinators, a patient representative, two experts in the field
and the study statistician. The independent data monitor-
ing committee (IDMC) includes an independent chair
expert in the field of prostate cancer therapy, a trial unit
manager and a senior statistician (all ofwhomare independent
of the study). This trial is registered in the clinicaltrials.gov
database (NCT01726894).2.2. Study population eligibility
Men with histologically proven MRI-visible prostate cancer
localised in the anterior part of the prostate. Therefore, onlymen
with disease in the transition area, the anterior fibromuscular
stroma or the peripheral zone of the prostate located in front
of the urethra will be considered eligible. Presence of clinically
significant disease outside the treated area represents an
exclusion criteria, but insignificant disease left untreated is
acceptable. A complete list of the eligibility criteria is given in
Table 1.
In this study, we use a definition specifically derived for
transperineal biopsies, as those definitions based on transrectal
biopsies have no proven validity in biopsies taken transperi-
neally. Our definition is based on the presence of any positive
core with primary or secondary Gleason pattern ≥ 4 (i.e., 3 + 4
or 4 + 3), and/or a maximum cancer core length ≥ 4 mm.
Insignificant disease is defined as opposite as Gleason 3+3with
maximum cancer core length of 3 mm or less.
Table 1
Inclusion and exclusion criteria for the NEAT trial.
Inclusion criteria
• Histologically proven prostate cancer, Gleason score ≤ 7.
• An anterior visible lesion on mpMRI, that is accessible to Irreversible
Electroporation.
• Transperineal prostate biopsies (template mapping and/or zonal and
targeted) correlating with clinically significant lesion in the area of the
MR-visible lesion.
• Absence of clinically significant histological disease outside of the
planned treatment zone.
• Stage radiological T1-T3aN0M0 disease, as determined by local
guidelines.
• Serum PSA ≤ 15 ng/ml.
• Age ≥ 40 years and life expectancy of ≥10 years.
• Signed informed consent by patient.
• An understanding of the English language sufficient to understand
written and verbal information about the trial and consent process.
Exclusion criteria
• Men who have had previous radiation therapy to the pelvis.
• Men who have had androgen suppression/hormone treatment within
the previous 12 months for their prostate cancer.
• Men with evidence of metastatic disease or nodal disease outside the
prostate on bone scan or cross-sectional imaging.
• Men with a non-visible tumour on mpMRI.
• Men with an inability to tolerate a transrectal ultrasound.
• Men with latex allergies.
• Men who have undergone prior significant rectal surgery preventing
insertion of the TRUS probe (decided on the type of surgery in
individual cases).
• Men who have had previous NANOKNIFE, HIFU, cryosurgery, thermal or
microwave therapy to the prostate.
• Men who have undergone a Transurethral Resection of the Prostate
(TURP) for symptomatic lower urinary tract symptoms within the prior
6 months. These patients may be included within the trial if deferred
from consent and screening until at least 6 months following the TURP.
• Men not fit for major surgery as assessed by a consultant anaesthetist.
• Men unable to have pelvic MRI scanning (severe claustrophobia,
permanent cardiac pacemaker, metallic implant etc likely to contribute
significant artefact to images).
• Presence of metal implants/stents in the urethra.
• Men with renal impairment with a GFR of b35 ml/min (unable to
tolerate Gadolinium dynamic contrast enhanced MRI).
Visit 1: Screening and Consent
Visit 2: Focal IRE treatment
Visit 3: Catheter removal and contrast-MRI
(3-10 days aer IRE)
Visit 4: Quesonnaires with PSA test
(6 weeks aer IRE)
Visit 5: Quesonnaires with PSA test
(3 months aer IRE) 
Visit 6:mpMRIand biopsy treated area 
Quesonnaires with PSA test
(6 months aer IRE)
Visit 7: Quesonnaires with PSA test
(9 months aer IRE) 
Visit 8: Quesonnaires with PSA test
Study terminaon
(12 months aer IRE)
Fig. 1. Trial flow.
59M. Valerio et al. / Contemporary Clinical Trials 39 (2014) 57–652.3. Trial design
The trial flow and the visit schedule are displayed in Figs. 1
and 2, respectively.2.3.1. Trial entry
It is of key importance to well select men who are likely to
benefit from focal treatment in which significant disease is
localised in only one part of the gland. To avoid the possibility
of leaving clinically significant cancer untreated, all patients
undergone state-of-the-art accurate imaging and tissue sam-
pling. Onlymen inwhich imaging and histology are concordant
in localising disease in the anterior part of the prostate were
eligible.
A mpMRI will be performed in a 1.5 Tesla or 3 Tesla scanner
and a pelvic phased array receiver with a pelvic coil using a
standardized protocol as described elsewhere [19]. The protocol
includes T2-weighted, dynamic contrast enhanced anddiffusion-
weighted images. The sequences used and the reportingmethod
will follow those laid down by the European society of uro-
radiology [20]. The images will be evaluated and reported byexperienced radiologists who will score the likelihood of
significant disease in a zonal fashion following international
guidelines [21]. MpMRI of the prostate using this protocol has
been shown to be able to rule out clinically significant disease
with a negative predictive value at 90–95% in centres of
excellence when compared to accurate reference tests [22,23].
All men will need also to undergo accurate biopsy using the
transperineal route. Both template prostatemappingwith 5mm
sampling density and zonal template biopsy with targeted
biopsy of MR-derived targets will be accepted. These tests have
been shown to be comparable in terms of diagnostic accuracy
and both yield a NPV again around 90–95% [24–27].
While no single test can definitely rule out clinically
significant disease, the combination of accurate imaging and
histology minimises (although not eliminates) the possible
miss-classification of untreated areas.
All men with a new diagnosis of prostate cancer are
counseled about all standard radical therapeutic options.
Those meeting the inclusion criteria for the NEAT trial are
offered a patient information sheet, and to attend a screening
and consent visit if interested. The consent, medical history,
physical examination, and blood tests including a PSA test are
collected. At baseline, a number of validated patient reported
outcome measures (PROMs) are completed: International
Prostate Symptom Score (IPSS) and IPSS Quality of Life (IPSS-
60 M. Valerio et al. / Contemporary Clinical Trials 39 (2014) 57–65QoL), 15-Item International Index of Erectile Function (IIEF-
15), UCLA Expanded Prostate Cancer Index Composite (EPIC)
urinary and bowel domains, EQ-5D Health related Quality-of-
life, Functional Assessment of Cancer Therapy for Prostate
(FACT-P) and Memorial Anxiety Scale for Prostate Cancer
(MAX-PC) [28–30]. Patients are also asked whether they want
to participate to an optional embedded qualitative study
aiming to assess patients' satisfaction with alternative elec-
tronic forms of follow-up.
2.3.2. Focal irreversible electroporation
Under general anaesthesia and deep muscle paralysis,
a suprapubic catheter or a urethral catheter, in case of
contraindication to a suprapubic catheter, are inserted.
The 19 G electrode-needles are inserted via a transperineal
approach under transrectal ultrasound (TRUS) guidance
using a brachytherapy grid. The electrical field in IRE is
created by positioning electrodes to the margins of the
tumour (Nanoknife™, AngioDynamics, New York, USA). The
number of electrodes used is dependent on the size and the
shape of the lesion to treat (Fig. 3). Usually, four electrodes
are required to cover a discrete lesion within the prostate,
although one additional electrode may be needed in larger
lesions. The device will be set to deliver 90 pulses with a
pulse length at 70 μs in order to achieve an electrical field
between 20 and 40 A. This current has been shown to cause
complete ablation in the target area without causing heating
effect, which in turn is possible when the current is higher
[31].
In this study, to allow precise placement of the electrode-
needles, a MR/TRUS fusion device is used. Various studies have
previously shown that integrating mpMRI images to real-time
TRUS images can be beneficial to better target intra-prostatic
tumours for biopsy and one previous study has shown
that fusion is feasible with HIFU focal therapy [32–34]. In the
NEAT trial we will use a high accuracy MR/TRUS fusion device
(SmartTarget) that by non-rigid registration compensates for
the distortion of the prostate [35,36]. This fusion device is
currently under development and commercialisation at UCL.
Since this is a pilot study, and the accuracy of this software is
yet to be defined for IRE focal therapy, the surgeon is free to
accept or reject the treatment planning calculated by the
software.
Once the electrodes have been positioned, the surgeon will
measure the distances between the electrodes and will select
the electrodes' active length according to the cranio-caudal
length of the target area. Based on these two measurements
which are manually entered in the device, the Nanoknife
software calculates the voltage necessary to obtain the optimal
electrical field (20–40 A). After the first 10 pulses have been
delivered, the actual electrical field in the prostatic tissue is
verified. If the electrical field is in the optimal range, then the
remaining 80 pulses are delivered; otherwise, the voltage is
modified as required.
The focal IRE treatment is planned as a day-case procedure.
Men arrive in the morning of the procedure, and are usually
discharged in the afternoon or in the evening. Catheter
withdrawal is scheduled between 3 and 10 days at the same
time of the early contrastMRI scan. Patients are prescribed pain
killers, antibiotics and laxatives for one week after the
procedure.2.3.2.1. Therapy escalation and rationale. Only men with MR-
visible anterior disease will be treated. At this early stage of
evaluation of this treatment, targeting the anterior part of the
prostate is the safest approach since it is away from the rectum.
As a consequence, rectal toxicity, and particularly the risk of
recto-urethral fistula are minimised since no previous clinical
study has accurately shown the extent of ablation that can be
achieved with IRE.
In this prospective development study, we have incorpo-
rated a ‘dose-escalation or dose optimisation’ protocol based on
target volume. Indeed, using a fixed algorithm including fixed
pulse length and number of pulses, the delivered energy is
mainly determined by the needle active length and by the
needle distances, which in turn are both derived by the target
volume. We are going to stratify the first nine patients into
three groups of three patients each based on amaximum target
volume. The ablation volume in millilitres has been calculated
with respect to an average prostate volume,which corresponds
to 40 ml. In the first group, a maximum of 4 ml ablation or
target volume representing maximum 15% of the prostate
volume is admitted. This represents the minimum amount of
tissue that is estimated to be possible to ablate in focal therapy.
The limit will be increased to 15 ml ablation or 40% prostate
volume, and to 20 ml ablation or 50% prostate volume, for
the second and third group, respectively. The upper
threshold corresponds to the maximum amount of tissue it
would be possible to treat in each subgroup of patients and
not a target to achieve. In the remaining 11 patients, the
upper threshold set at 20ml ablation or 50% prostate volume
will be respected.
2.3.3. Follow-up
After discharge from the hospital, an early contrast-MRI is
organised to assess the ablation of the target area, and to rule out
significant damage to structures adjacent to the prostate.
Outpatient visits will occur at 6 weeks, 3, 6, 9 and 12 months.
At each, adverse events will be ascertained, PROMs used at
baseline are filled and serumPSA levelmeasured. At 6months, all
men undergo a mpMRI and targeted biopsy of the treated area.
The biopsy density is set to at least 1 targeted biopsy per 1–2 ml
residual prostate volume. Untreated areaswill be sampled only if
a new suspicious lesion is detected on the 6months mpMRI or if
there is a suspicious change in another area. This sampling
strategy aims to minimise the possibility of biopsy-related
adverse events by avoiding further sampling of untreated areas,
which in the case of a negative mpMRI and a recent template
negative biopsy is unlikely to harbour significant disease. As per
standard practice, ‘for cause tests’ are permissible at any time
point. For instance, a significant unexplained rise in the PSAmay
drive additional mpMRI scans and/or additional biopsy.
2.3.4. Testing alternative forms of follow-up
Patients will be offered an optional embedded qualitative
study. This aims to evaluate patient satisfaction in the use of
telephone consultation as well as with electronic tools for
filling questionnaires. We aim to collect pilot data on patients'
satisfaction, usability and acceptability with the use of these
tools offering different strategies at different time-points.
Patients in this nested studywill have a telephone consultation
at 6 weeks and will receive their questionnaires at home by
post. At 6 months, patients will have a normal clinic visit, but
Strategy 1: Telephone follow-up with paper-based questionnaires posted to patient
Strategy 2: Clinic visit with electronic completion of questionnaires on e-tablet computer 
Strategy 3: Telephone follow-up with online completion of questionnaires
Visit 1 2 3(3-10 days)
4
(6 weeks)
5
(3 months)
6
(6 months)
7
(9 months)
8
(12 months)
Consent X
PSA blood test X X X X X X
Questionnaires Pack 1
(IPSS, IPSS-QoL, IIEF-15, 
EPIC-urinary, EPIC bowel, 
EQ-5D QoL)
X X X X X X X
Questionnaires Pack 2
(FACT-P, MAX-PC) X X X
MRI X X
Targeted biopsy of the 
treated area X
Focal Irreversible 
Electroporation X
Catheter removal X
Fig. 2. Single visit schedule throughout the trial. Patient in the embedded qualitative study will have visits 4, 6 and 7 carried out in an alternative electronic manner, as
shown in the table and legends.
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computer in the research clinic prior to meeting the clinician.
At 9 months, patients will have a telephone consultation and
will complete online questionnaires. Finally, following the last
clinic visit at 12 months, men in the embedded study will be
interviewed using a standardized semi-structured question-
naire. The interviews will last around 30 min, and will be
audiotaped and transcribed. Thematic extraction will be used
to determine whether these men found the method of data
collection acceptable, easy to use and would continue to use it.
Direct anonymised quotes will be used to illustrate particularFig. 3. This a representative diagramof the treatment planning for irreversible electropo
of a TRUS, respectively. The electrodes are positioned around the lesion to treat (left ima
right image) is determined according to the longitudinal dimension of the lesion.themes which evolve. The purpose of the embedded study will
be to determine optimal and cost-effective follow-up methods
in future studies.
2.3.5. Stopping rules
In case a recto-urethral fistula, assessed clinically or
radiologically, occurs in any one patient at any time, the IDMC
will review the case and make recommendations to the TSC.
Any further treatments will be halted while this occurs. We
envisage that the target volume will be reduced to the
preceding maximum volume. If a recto-urethral fistula occursration of the prostate. Left and right images represent an axial and sagittal views
ge), highlighted as a red spot. A given active length exposure (blue arrow in the
62 M. Valerio et al. / Contemporary Clinical Trials 39 (2014) 57–65in more than one patient, the IDMC and TSC will evaluate
whether it is safe to proceed with the trial.
2.3.6. Objectives
The primary objective is to determine the adverse events,
genito-urinary and rectal side-effect profile at 12 months after
focal IRE.
There are a number of secondary objectives included in
the study. First, to collect pilot data on the disease control
rates of focal IRE for the treatment of prostate cancer localised in
the anterior part of the prostate using post-treatment biopsy.
Second, to report the rate of patients achieving a trifecta (pad-
free/leak-free urinary continence, erections sufficient for pene-
trative intercourse, and absence of clinically significant disease in
the treatment area). Third, to determine domain-specific genito-
urinary, rectal toxicity and health-related quality of life after IRE.
Fourth, to obtain pilot data on the utility ofmpMRI in the follow-
up of focal IRE. Fifth, to explore the utility of using a MR/TRUS
fusiondevice for delivering focal IRE. Finally, inmenparticipating
within the embedded qualitative study, we will assess patient
usability, acceptability and satisfaction in the use of electronic
tools and in telephone consultations.
2.3.7. Statistical analysis
2.3.7.1. Sample size calculation. As the primary objective of the
study is to determine the toxicity profile of focal IRE, the sample
size was calculated on the basis of common adverse events,
which are urinary incontinence and erectile dysfunction.
Further, since the results could be used to progress to a IDEAL
stage 2b multi-centre therapeutic confirmatory study with 2–3
years of follow-up, it is essential to have a sample size that gives
appropriate precision around these key outcomes. Considering
an expected proportion of pad-free/leak-free urinary continence
of 95%, and a rate at 10% of erectile dysfunction, the ±95% CI
around such proportionswith n=10, n=20 and n=25would
be at 13.5%, 9.55% and 8.5% for incontinence, and at for 18.6%,
13.2% and 11.8% for erectile dysfunction, respectively. We have
therefore chosen to set the sample size at n = 20, as there is
significant increased precision from n = 10 (Δ = 3.95% and
5.4%), but little improvement is achieved if more patients are
included (Δ= 1.05 and 1.4%).
2.3.7.2. Primary outcome. Primary outcomewill bemeasured by
PROMs evaluating sexual, urinary and rectal toxicity. Sexual
outcome will be estimated by the rate of men with erectile
dysfunction, defined by an inability to have erections sufficient
for penetrative intercourse, as measured by the IIEF-15 ques-
tionnaire. Primary and secondary outcomes will be reported
along with 95% confidence intervals.
2.3.7.3. Secondary outcomes. Various outcome measures will be
used according to the specific outcome of interest. The rate of
clinically significant disease and of any disease will be calculated
using the findings of targeted biopsy of the treated area at 6
months. Adding this rate to sexual and continence primary
outcomes, we will estimate the rate of trifecta status achieve-
ment. The proportion of domain-specific genito-urinary and
rectal toxicity as well as health-related quality of life will be
estimated using validated questionnaires (IPSS, IPSS-QoL, IIEF-
15, UCLA-EPIC urinary and bowel domain, EQ-5D QoL, FACT-Pand MAX-PC). The utility of mpMRI in detecting residual/
recurrent disease will be evaluated against follow-up biopsy
(reference test) to calculate point estimates of sensitivity,
specificity, negative and positive predictive values. Pilot data on
the utility of MR/TRUS fusion device for delivering focal IRE will
be evaluated by the proportion of men in which the planned
treatment volume was changed. The use of electronic tools and
of telephone follow-up after treatment will be evaluated by a
qualitative thematic analysis.
3. Discussion
NEAT is an IDEAL prospective development 2a study.
As opposed to new drug development, in which the pathway
is rigorous, established and protected by strict observance
of rules, the assessment of new technologies in surgery is
recognised to be more fluid, less rigorous, and commonly
based on retrospective rather than on prospective study
designs. There are a number of factors that make surgery a
more difficult field in which to apply multi-step rigorous
study designs: the complexity of interventions, the learning
curve, and the surgeons' and patients' equipoise. The re-
cognition of these issues has led to the development of
a specific pathway for the evaluation of novel surgical
procedures, which is more feasible in the surgical environ-
ment, and at the same time ensures patients' safety and
meaningful results [13,37,38].
Following on from pre-clinical studies testing IRE and
one stage I trial, NEAT represents the next natural step in the
assessment of this new technology for treating localised
prostate cancer. The study population, the intervention and
the selected outcomes have been chosen to achieve mean-
ingful results by which to determine whether a larger trial is
necessary.
One area that requires further elaboration is the definition
of what constitutes clinically significant prostate cancer.
In other words, disease that would otherwise impact on a
man's quality of life or life expectancy, if left untreated. There
is no general consensus on what represents clinically signifi-
cant prostate cancer, but it is well recognised that most
prostate cancers do not impact on survival. Nonetheless, there
is strong evidence that tumour stage, grade and volume are
substantial features of clinically significant disease. In localised
prostate cancer, Gleason grade is themost significant predictor
of mortality. In large cohort studies, patients with pure Gleason
3+ 3 had rarely metastasised or died from their disease over a
15 year period of follow-up [4,39]. As in other malignancies,
cancer volume is also a determinant of aggressiveness, but the
threshold volume has not been determined. Historically,
thresholds between 0.2 and 0.5 ml have been considered
significant, although one recent study based on the findings of a
large European RCT (ERSPC) has shown that this volume may
be up to 1.3 ml in a screened population [40,41]. We will
carefully select men using state-of-the-art diagnostic tests
(mpMRI and template with targeted biopsy) that have the
ability to minimise the possibility of disease misclassification
and leaving clinically significant disease untreated. The strict
histological classification used for significant disease in partic-
ular predicts thepresence of a lesionwith volume≥ 0.2mlwith
over 95% sensitivity [42]. The population of men is therefore
likely to benefit most from undergoing a tissue-preserving
63M. Valerio et al. / Contemporary Clinical Trials 39 (2014) 57–65approach that can potentially combine the oncological benefit
with preservation of function. In addition, the selection of only
men with anterior disease makes the possibility of recto-
urethral fistula, which represents the most significant compli-
cation after focal therapy in prostate cancer, very unlikely to
happen.
IRE is a procedure with potentially attractive characteristics
which may be ideal for delivering focal therapy in the prostate
especially as it has been shown to have tissue-selectivity in pre-
clinical models [8]. Animal studies have demonstrated that the
application of therapeutic IRE led to homogeneous ablation
of prostatic tissue with preservation of collagenous structures,
which in the prostate means the urethral sphincter, the
neurovascular bundles, and the urethra [11]. If this was true
in clinical studies such as NEAT, the most significant side-
effects of prostate treatments, namely urinary incontinence
and erectile dysfunction may be further minimised. The
application of IRE in a homogeneous group of men in a
standardized fashion will assist to appropriately verify these
aspects of the technology.
Some discussions of the secondary efficacy parameters that
we propose to use are warranted here. Most previous studies
assessing the efficacy of various sources of energy to deliver
focal therapy in the prostate have been negatively impacted by
the absence of systematic assessment of ablative success or
failure [6]. This is a key methodological problem in the
assessment of treatments for prostate cancer. Indeed, as the
natural history is prolonged, and these early studies have short
to medium follow-up, survival is difficult to include as an
outcome measure of oncological efficacy, so the incorporation
of reliable surrogate outcome measures has gained some merit
[6]. While PSA is considered a valid outcome measure for
radical prostate cancer treatments, it is not validated after focal
therapy and due to the ongoing secretion of PSA by untreated
tissue might not be valuable. Also, although the selection of only
men with MR-visible lesions makes the detection of oncological
failure potentially easier with imaging, mpMRI is also not
validated as ameasure of local control after IRE although studies
have shown its utility after HIFU and cryotherapy [43,44]. As a
consequence of these comments, the only reliable measure of
ablation remains the histological analysis of the tissue in the
treatment area, which in this study in included with a high
sampling density.
3.1. Study limitations
The first limitation is linked to one of the advantages for
patients in terms of safety, which is the anterior location of the
prostatic cancer as this limits external validity of the treatment
since around two-thirds of prostatic cancers are located in the
posterior prostate which is histologically different to the
anterior prostate and thus IRE may have different effect. Thus,
as the successful treatment of the target area is closely linked to
the inner electrical characteristics of that target, the success or
the failure of the treatment of the anterior prostate would not
extrapolate to a similar result if the same treatment were
applied to the posterior prostate.
Further, the study is a single centre trial in a tertiary hospital
particularly expert with focal therapy and needle-based
transperineal prostate procedures; therefore, the results of
this study are unlikely to allow wide generalization. While weacknowledge this limitation, and clearly multi-centre studies
will be necessary, the single centre expert setting is the
preferred context in which to allow ideal development of
new technologies.
Another limitation may be the validity of PROMs filled using
alternative methods, for those men participating to the nested
qualitative study. Validated PROMs represent robust instru-
ments for assessing a given outcome, but paper-based question-
naires completed during a clinic visit may not represent the
optimal manner by which to collect them. Also, clinic visits
themselves, although necessary in a trial setting, when part of
standard care if a trial determined this so, oblige patients to
physically come every time, which is both time-consuming and
expensive for the patient and expensive for a healthcare system.
The use of telephone follow-up and of electronic tools might
address this timely issue and various models have been shown
to be successful [45]. However, the validity of such tools has not
been compared to traditional paper-based questionnaires in the
setting of experimental prostate cancer treatments. There might
be a verification bias as men might respond differently when
using such tools.While we accept this as a limitation, we believe
this study is justified by the need for determining the satisfaction
of men with these tools, which if positive can enhance trials
feasibility. In addition, all the electronic tools were used in
interim visits, whereas baseline and last-visit PROMs were
completed in a traditional manner. Thus, the variation in time
might be affected, but the final outcome will not.
4. Conclusion
The NEAT trial will allow an appropriate evaluation of focal
IRE in men with localised prostate cancer by using validated
patient reported outcomes and systematic assessment of local
efficacy. The outcomes of NEAT may be used to progress to a
large confirmatory multi-centre trial. This adaptive design may
provide guidance in the challenging landscape of health
technology assessment in prostate cancer therapy.
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